Ivermectin

Ivermectin, the active ingredient in Ivermectin, is an Anthelmintic presented as a tablet for Oral use. It treats parasitic infections such as onchocerciasis, strongyloidiasis, lymphatic filariasis, scabies and pediculosis in affected individuals.

GNH USA supplies Ivermectin as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivermectin is used to treat a range of helminth and ectoparasite infections. - Onchocerciasis: reduces microfilarial load and helps prevent blindness. - Strongyloidiasis: eradicates intestinal larvae and prevents systemic dissemination. - Lymphatic filariasis: eliminates adult worms and microfilariae to control disease spread. - Scabies: kills Sarcoptes scabiei mites, relieving itching and skin lesions. - Pediculosis: eliminates head lice infestations, reducing transmission.

Ivermectin may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools occurring shortly after dosing. - Dizziness: transient light‑headedness. - Abdominal pain: cramping or discomfort. - Pruritus: itching at the site of parasite death. - Headache: mild tension‑type headache.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Hepatic injury: elevated liver enzymes or jaundice. - Severe hypotension: sudden drop in blood pressure. - Seizures: rare neurologic events. - Anaphylaxis: acute allergic reaction with airway compromise. - Visual disturbances: blurred vision or optic neuritis.

Before prescribing Ivermectin, clinicians should consider several safety measures. - Assess for Loa loa infection: avoid in patients with high microfilaremia due to risk of severe reactions. - Review liver function: adjust use in hepatic impairment. - Monitor neurologic signs: watch for dizziness, seizures, or altered mental status. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Use caution in pregnancy: safety category unknown, weigh benefits against risks. - Store at ambient temperature: keep in the original pack, protect from moisture.

Ivermectin can interact with other medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase ivermectin plasma levels. - Warfarin: concurrent use may enhance anticoagulant effect and bleeding risk. - Other neurotoxic antiparasitics (e.g., albendazole): may increase neurotoxicity. - P‑glycoprotein inhibitors (e.g., verapamil): can raise systemic exposure. - QT‑prolonging agents: combined use may raise arrhythmia risk.

Moderate Interactions (Monitor Closely): - CYP3P4 inducers (e.g., rifampin): may reduce ivermectin effectiveness. - Additional antiparasitics: monitor for additive side effects. - Anticoagulants other than warfarin: observe coagulation parameters. - Statins: watch for signs of myopathy. - Antihistamines: may increase sedation.